We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
|---|---|---|---|---|---|
| Phynova | LSE:PYN | London | Ordinary Share | GB00B0YBCM49 | ORD 1P |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| 0.00 | 0.00% | 1.375 | 0.00 | 01:00:00 |
| Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
|---|---|---|---|---|---|
| 0 | 0 | N/A | 0 |
Hot Features
Premium
TIDMPYN
RNS Number : 7215U
Phynova Group PLC
30 June 2009
30 June 2009
Phynova Group plc
("the Company")
Total Voting Rights
The Company announces that, pursuant to the requirements of the Disclosure and
Transparency Rules, the total number of voting rights in respect of each class
of share in issue and admitted to trading on AIM at the date of this
announcement is as follows:
+-----------------------------------------+--------------+--------------+
| | Number of | Numbers of |
| | shares in | voting |
| | issue | rights |
+-----------------------------------------+--------------+--------------+
| Ordinary shares of 1p each | 31,716,726 | 31,716,726 |
+-----------------------------------------+--------------+--------------+
| | | |
+-----------------------------------------+--------------+--------------+
For further information, please contact:
+----------------------------------------------------+---------------------+
| Phynova Group PLC | |
+----------------------------------------------------+---------------------+
| Steve Harris (Non-Executive Chairman) | +44 (0) 1993 880700 |
+----------------------------------------------------+---------------------+
| Tony Mills (CEO Phynova Limited) | |
+----------------------------------------------------+---------------------+
| Robert Miller (CEO Phynova China Limited) | |
+----------------------------------------------------+---------------------+
| | |
+----------------------------------------------------+---------------------+
| Nominated Adviser and Broker: | |
+----------------------------------------------------+---------------------+
| John East & Partners Limited, a subsidiary of | +44 (0) 20 7628 |
| Merchant Securities PLC | 2200 |
+----------------------------------------------------+---------------------+
| John East/Simon Clements | |
+----------------------------------------------------+---------------------+
| | |
+----------------------------------------------------+---------------------+
Notes to Editors:
About Phynova
Phynova is a UK company developing new prescription pharmaceuticals derived from
plants used in Chinese medicines. The Company is focused on viral and bacterial
diseases, metabolic diseases and cancer. Phynova's lead product for hepatitis C
has now completed a Phase I/II trial in the US. One further product, for
post-operative ileus, is targeted for entry to the clinic and there are a
further four products in preclinical development.
For further information please visit www.phynova.com.
This information is provided by RNS
The company news service from the London Stock Exchange
END
TVRBLGDLDDDGGCC
1 Year Phynova Chart |
1 Month Phynova Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
